Congress tightens 340B drug program: stricter rules, patient caps, steep penalties
H.R. 5256 — 340B ACCESS Act · Filed by Buddy Carter (R-GA) · 1 cosponsor · Introduced Sep 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reforms the 340B drug pricing program, which allows certain hospitals and clinics to buy discounted drugs from manufacturers. The bill tightens eligibility rules for hospitals' off-campus facilities (requiring them to serve low-income patients and meet specific Medicare standards), limits hospitals to 5 contract pharmacies, requires hospitals to cap patient out-of-pocket costs ($0 for those below poverty, $35–$50 for others), and imposes strict compliance audits and penalties ($2,500–$3,000 per violation) on both covered entities and pharmacies. It also requires manufacturers to ship drugs only to registered addresses and mandates annual public reporting of compliance.
Why we flagged it
The bill's core mechanism is regulatory tightening of the 340B program—stricter eligibility, compliance audits, and penalties—paired with new patient affordability requirements. It is neither a pure deregulation nor a pure expansion; it is a restructuring that imposes obligations on both covered entities and manufacturers while creating patient protections.
What the text implies
- The $25,000 annual in-kind contribution threshold for subgrantees may exclude smaller community health centers from participating, concentrating program benefits among larger institutions.
- Requirement that off-campus facilities be located in health professional shortage areas (HPSA) may prevent hospitals from expanding 340B access in underserved rural or suburban areas not formally designated as shortage areas.
The full analysis lists 5 implications of this text.
Who stands to gain
Pharmaceutical manufacturers (reduced duplicate discounting, clearer compliance pathways); Large hospital systems (able to absorb compliance costs and maintain 5 contract pharmacies); Larger pharmacy chains (consolidation advantage as smaller independents exit)